Nucleolin could potentially serve as a broadly useful target to deliver therapeutics to tumor cells in vivo, and the nucleolin aptamer developed by Bates and colleagues that binds to both murine and human nucleolin17 could represent an all but universal tumor-targeting ligand. Here, NUCLEOLIN is linked to neoplasm.